Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer

International Journal of Radiation Oncology, Biology, Physics
Steven E SchildJames R Jett

Abstract

This Phase III study was performed to determine whether twice-daily (b.i.d.) radiotherapy (RT) resulted in better survival than once-daily (q.d.) RT for patients with limited-stage small-cell lung cancer (LD-SCLC). A total of 310 patients with LD-SCLC initially received three cycles of etoposide and cisplatin. Subsequently, the 261 patients without significant progression were randomized to two cycles of etoposide and cisplatin plus either q.d. RT (50.4 Gy in 28 fractions) or split-course b.i.d. RT (24 Gy in 16 fractions, a 2.5-week break, and 24 Gy in 16 fractions) to the chest. Patients then received a sixth cycle of etoposide and cisplatin followed by prophylactic cranial RT. Follow-up ranged from 4.6 to 11.9 years (median, 7.4 years). The median survival and 5-year survival rate from randomization was 20.6 months and 21% for patients who received q.d. RT compared with 20.6 months and 22% for those who received b.i.d. RT (p = 0.68), respectively. No statistically significant differences were found in the rates of progression (p = 0.68), intrathoracic failure (p = 0.45), in-field failure (p = 0.62), or distant failure (p = 0.82) between the two treatment arms. No statistically significant difference was found in the overall r...Continue Reading

References

Dec 3, 1992·The New England Journal of Medicine·J P PignonB Lebeau
Dec 19, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stein SundstrømUNKNOWN Norwegian Lung Cancer Study Group

❮ Previous
Next ❯

Citations

Sep 15, 2004·Cancer Chemotherapy and Pharmacology·Minoru FukudaUNKNOWN Nagasaki Thoracic Oncology Group
Jul 14, 2009·International Journal of Clinical Oncology·Sherif AbdelwahabIbrahim Dwedar
Apr 30, 2013·Current Oncology Reports·Gregory M M Videtic
Mar 1, 2007·Nature Clinical Practice. Oncology·Søren M BentzenJacques Bernier
Feb 8, 2006·Current Opinion in Oncology·Carrie B LeeMark A Socinski
Mar 21, 2013·American Journal of Clinical Oncology·Feng-Ming KongUNKNOWN Expert Panel on Radiation Oncology-Lung
Jan 19, 2007·International Journal of Clinical Practice·L WatersM Nelson
Feb 11, 2010·The Oncologist·Thomas E Stinchcombe, Elizabeth M Gore
Aug 20, 2005·The British Journal of Radiology·C PlathowH-U Kauczor
Jun 30, 2011·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·Martin FrühLudwig Plasswilm
Dec 25, 2007·Wiener klinische Wochenschrift·Stefan HoschekUNKNOWN Tiroler Arbeitskreis für Onkologie TAKO
Jun 7, 2011·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Neha P AminLaurie E Gaspar
May 30, 2013·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Joseph K SalamaUNKNOWN Cancer and Leukemia Group B
May 31, 2011·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Jeffrey A Bogart
Jun 5, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Michael NgDavid Ball
Oct 6, 2007·Chest·David J SamsonUNKNOWN American College of Chest Physicians
Apr 13, 2012·Current Problems in Cancer·Paul D AridgidesJeffrey A Bogart
Sep 29, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·David Planchard, Cécile Le Péchoux
Nov 8, 2011·Clinics in Chest Medicine·Joel W NealHeather A Wakelee
Oct 12, 2011·Surgical Oncology Clinics of North America·Seth D Goldstein, Stephen C Yang
Mar 1, 2011·International Journal of Radiation Oncology, Biology, Physics·Ben J Slotman, Suresh Senan
Aug 17, 2010·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·M K A HerrmannO Pradier
Dec 30, 2015·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·A BeddokM Faraldi
Aug 12, 2009·International Journal of Radiation Oncology, Biology, Physics·Natsuo TomitaHaruo Inokuchi
Oct 22, 2008·Seminars in Oncology·Axel GrotheyUNKNOWN North Central Cancer Treatment Group
Aug 16, 2005·Clinical Lung Cancer·Corinne Faivre-FinnNick Thatcher
Aug 5, 2008·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·N A BaymanC Faivre-Finn
Oct 31, 2007·Clinics in Chest Medicine·Lynn T Tanoue, Scott Gettinger
Dec 23, 2006·Seminars in Thoracic and Cardiovascular Surgery·Masaki Anraku, Thomas K Waddell
May 30, 2006·Hematology/oncology Clinics of North America·Feng-Ming Spring KongJames A Hayman
Jul 6, 2004·International Journal of Radiation Oncology, Biology, Physics·Andrew T Turrisi
Jul 19, 2006·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Hye Cheol JeongSe Hwa Yoo
Mar 28, 2006·International Journal of Radiation Oncology, Biology, Physics·Don YeeWilson Roa
Dec 24, 2005·Clinical Oncology : a Journal of the Royal College of Radiologists·C Faivre-FinnN Thatcher

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved